Identity
- Security key
- 19630
- Ticker
- OMER
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2009-10-08
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- OMER
Detail
Enriched 2026-08-14 20:47
- Market cap
- $992,266,117.05
- Shares outstanding (class)
- 72,375,355
- Shares outstanding (weighted)
- 72,375,355
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 175
- Location
- SEATTLE, WA
- Homepage
- https://www.omeros.com
- Description
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Market cap and share counts drift.